

SUPPLEMENTARY APPENDIX

1. **ConPlas-19 Study Team and organization**
 2. **Supplementary Methods**
 3. **Supplementary Tables**
 4. **Supplementary Figures**
-

1. ConPlas-19 Study Team and organization

Steering Committee:

Rafael F Duarte, Antonio Ramos, José Luis Bueno, Elena Muñoz, Cristina Avendaño-Solà, Belén Ruiz-Antorán, Rosa Malo de Molina, Ferran Torres, Inmaculada Casas Flecha

Project Principal Investigators: Cristina Avendaño-Solà and Rafael F. Duarte

Clinical Trial National Coordinator: Antonio Ramos

Convalescent Plasma National Coordinator: José Luis Bueno

Data Safety Monitoring Board (DSMB):

Arantxa Sancho-López (chair), Emilio Ojeda, José Ríos, Carlos Vilches, Juan Antonio Vargas

Safety Medical Officer:

Concepción Payares-Herrera

Respiratory Virus Laboratory: Inmaculada Casas, Francisco Pozo

Serology Laboratory: Mayte Pérez-Olmeda

AIDS Immunopathogenesis Unit: Javier García-Pérez, José Alcamí

ConPlas-19 Study group Members:

Hospital Universitario Puerta de Hierro-Majadahonda: Antonio Ramos, Elena Muñoz, Ana Fernández-Cruz, Alejandro Callejas, Jorge Calderón, Isabel Salcedo, Rocío Layunta, Concepción Payares-Herrera, Elena Diago-Sempere, Antonio Caballero-Bermejo, Belén Ruiz-Antorán, Cristina Avendaño-Solà, Irene Romera, José Luis Bueno, Rafael F Duarte

Hospital Universitario 12 de Octubre: Jaime Lora-Tamayo, Mikel Mancheño-Losa, Carlos Lumbreras-Bermejo, Joaquín Martínez-López, María Liz Paciello, Carolina Villegas Da Ros

H. U. Clínico San Carlos: Vicente Estrada, María Isabel Sáez-Serrano

H. G. U. de Ciudad Real: María Lourdes Porras-Leal, María del Castillo Jarilla-Fernández, Francisco Javier González-Gasca, Giselle Victoria Andújar-Troncoso, Ana María García-Pérez, Inés Almagro-Treviño

H. C. U. Lozano Blesa Zaragoza: José Ramón Paño-Pardo, José Antonio Moreno-Chulilla

H. del Mar: [Hernando Knobel](#), [Itziar Arrieta-Aldea](#), [Gabriela Ene](#), [Alba Bosch](#), [Alicia González](#)

H. U. Salamanca: Moncef Belhassen-García, Olga López-Villar

H. U. Ramón y Cajal: Javier Martínez-Sanz, Gemma Moreno

H. Sant Joan de Deu de Manresa. Fundación Althaia: Antonia Flor Pérez, Albert Altés-Hernández

H. U. Marqués de Valdecilla: María del Carmen Fariñas, Iñigo Romón-Alonso

H. Clínico U. de Valladolid: Carlos Jesús Dueñas-Gutiérrez, Ignacio de la Fuente-Graciani

Complejo Hospitalario de Toledo: Angel Sánchez-Castaño, Ángel Luis Pajares-Herraiz

H. General de Albacete: José Javier Blanch-Sancho, Elena Gutiérrez-Gamarra

H. U. Miguel Servet: Estibaliz Jarauta-Simón, Victoria Paz González-Rodríguez

Other participating centres with no patients recruited:

H. U. Severo Ochoa de Leganés, H. U. Príncipe de Asturias de Alcalá de Henares, H. U. Gregorio Marañón de Madrid, H. U. Princesa de Madrid, H. U. Central de Asturias, Complejo H. de Navarra, H. U. HM Sanchinarro, Clínica Universidad de Navarra (CUN), Complejo Asistencial U. de León, Hospital General U. de Valencia, H. U. Arnau de Vilanova de Lleida, H. U. Sant Joan de Reus, H San Pedro de Rioja, H. U. Mútua de Terrassa, H. Dr. Josep Trueta de Girona, H. Dr. Negrín de Canarias, H. U. Quironsalud de Pozuelo, H.U. Donostia.

Participating Transfusion Centres:

Centro de Transfusión de las Fuerzas Armadas: Ascensión Ramos-Garrido, Juan Carlos López-Aguilar

Banco de Sangre y Tejidos Aragón: José M^a Domingo-Morera

Banc de Sang i Teixits de Catalunya: Alba Bosch, Enric Contreras, Eduardo Muñiz

Centro de Hemoterapia y Hemodonación de Castilla y León: Lydia Blanco, M. Isabel González-Fraile, Carmen Martín

Centro de Transfusión de Ciudad Real: María Elena Madrigal-Sánchez, María Pilar Muñoz-Valbuena, María Almudena García-Núñez de Arenas, María Pilar Muñoz-León, María Paz Cid-Sánchez, María Caridad Morales-Encinas

Centro de Transfusión de la Comunidad de Madrid: Ana Arruga

Project management and monitoring:

Spanish Clinical Research (SCReN) Network, Instituto de Salud Carlos III : Ana Velasco, Álvaro Veiga

Data management and Statistics:

PIVOTAL (CRO): José Javier García, Aitor Pérez, Francisco José Montane, Olga Fernández

2. Supplementary Methods

Additional details on laboratory assays

-RT-PCR assays

Specimens were taken from each donor and patient at admission and were sent for virologic investigation to the Respiratory Viruses and Influenza Laboratory (CNM-ISCIII). Samples were stored at 4°C and processed within 24 hours after collection. Upon reception, 3 aliquots were prepared and stored at -80°C. Both the reception and the sample processing areas are separated from those defined as working areas. RNA from 200-µL aliquots of oro/nasopharyngeal swab specimens and 400-µL aliquots of blood sample were extracted by using the QIAamp Mini Elute Virus spin kit in an automated extractor (QIAcube; Qiagen, Valencia, CA).

Every specimen from donors and patients were analysed by RT-PCR assay with targets in the E and N genes as previously described (1). This protocol was modified in order to include a simultaneous amplification of human DNA as internal control and was modified and adapted at the reagents and CFX96 termociclador at the Respiratory Virus and Influenza Laboratory at the Microbiology National Centre (CNM, ISCIII). Values of Cts showed a semiquantitative measure of the viral load in the non-homogeneous respiratory samples.

1. Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25, 1–8 (2020).

- Immunoassay for SARS-CoV-2 antibody testing

The Euroimmun Anti-SARS-CoV-2 ELISA IgG assays (Euroimmun, Luebeck, Germany) were performed on serum samples according to the manufacturer's instructions. The microplate wells are coated with recombinant structural protein 1 (S1) of SARS-CoV-2 and the assay detects anti-SARS-CoV-2 IgG against the viral spike protein. The results are evaluated semi-quantitatively by calculation of the ratio between the extinction of the sample and calibrator. A ratio <0.8 is considered negative, ≥ 0.8 and <1.1 borderline, and ≥ 1.1 positive.

-Pseudovirus Assays.

Materials.

The Vero E6 (African green monkey kidney) cell line were kindly provided by Dr. A. Alcami (CBM Severo Ochoa, Madrid). HEK-293T (National Institute for Biological Standards and Control (NIBSC)) and Vero E6 cells were cultured in DMEM supplemented with 10% FCS, 2 mM L-glutamine and 100 units/ml penicillin and streptomycin (Lonza).

For the generation of the expression plasmid for SARS-Cov-2 S glycoprotein, the codon-optimized cDNA (QHU36824.1) lacking the last 19 amino acids (1) was synthesized (GeneArt Gene Synthesis, ThermoFisher Scientific), PCR-amplified and cloned into the pcDNA3.1 expression vector (Invitrogen). Complete DNA sequence of S glycoprotein in pcDNA3.1-SARS-Cov2-S Δ 19 was confirmed by sequencing. The pcDNA-VSV-G plasmid contains the cDNA encoding the vesicular stomatitis virus G protein and was obtained from Dr. Arenzana-Seisdedos (Institute Pasteur, Paris, France).

Pseudovirus neutralization assay.

NL4.3 pseudotypes were generated with the previously described plasmid pNL4-3 Δ envRen (2). Briefly, Renilla luciferase reporter pseudovirus were prepared by co-transfecting HEK-293T cells with pNL4-3 Δ envRen backbone and viral envelope protein expression plasmid pcDNA3.1-SARS-Cov2-S Δ 19 or pcDNA-VSV-G using the calcium phosphate method. The medium was changed 18 hours after transfection, and 48 hours post-transfection cell culture supernatants were harvested, clarified by centrifugation at 500 x g for 5 min, and frozen at -80 °C. The amount of p24 antigen in the supernatants was quantified by electrochemiluminescence Immunoassay (Roche Diagnostic).

To measure neutralization activity of sera from COVID-19 patients or healthy donors, two-fold serial dilutions of heat-inactivated sera (1/16-1/4096) were preincubated with titrated pseudoviruses (10 ng p24 Gag/well) for 1 hour at 37°C. Thereafter, 100 μ l of the mixture was added to Vero E6 cells plated at 5 x 10³ cells/well in 100 μ l medium in 96-well plates the previous day. The culture medium was refreshed after 16 hours. At 48 h post-infection, cells were lysed, and viral infectivity was assessed by measuring luciferase activity (Renilla Luciferase Assay, Promega, Madison, WI) using a 96-well plate luminometer "Orion" (Berthold, Oak Ridge, TN). The titers of neutralizing antibodies were calculated as 50% inhibitory dose (ID50), expressed as the highest dilution of plasma, which resulted in a 50% reduction of luciferase activity compared to control without serum. Sigmoid curves were generated and ID50 neutralization titers were calculated by non-linear regression using GraphPad Prism version 7.02 (GraphPad Software, Inc.). VSV-G pseudoviruses were used as a specificity control virus in neutralization testing.

1. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun.* 2020;11: 1620.
2. Garcia-Perez J, Sanchez-Palomino S, Perez-Olmeda M, Fernandez B, Alcami J. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. *J Med Virol.* 2007 Feb;79(2):127-37.

-Virus Microneutralization test (VMNT).

Serum neutralization was measured using replication competent virus in a the process that requires 2 days and was conducted in a biosafety level 3 laboratory for containment of SARS-CoV-2 at the Microbiology National Centre (CNM, ISCIII).

The neutralization capacity of serum samples was measured against our reference Spanish isolate of SARS-CoV-2 (GISAID ID EPI_ISL 418248) at working dilution of 100xTCID50 (50% tissue culture infectious dose) by using VERO E6 clone C1008 ATCC® CRL-1586 cultured in DMEM (Gibco) supplemented with 10% Fetal Calf Serum (MP Biomedicals), 1 mM L-glutamine and 100 units/ml penicillin and streptomycin (Sigma) in 96-well plates. Cell culture low passage monolayers were used at 70-95% confluence.

Virus microneutralization assay based on the standard WHO reference influenza microneutralization assay, modified for MERS-CoV and SARS-CoV-2 (1,2). Briefly, 2-fold serially diluted in PBS (in duplicate) heat-inactivated samples (56°C for 45 min), were made starting at a dilution of 1:16 in 50 µL. Then, 50 µL of virus solution containing 100xTCID50 in MEM were added to each well in a 96-well cell culture plate and allowed to incubate for 1 h at room temperature, before placing 100 µL of diluted Vero-E6 cells (1,5 x 10⁵ cells/mL) and incubated for 18-20h at 37°C. After incubation, we fixed the cells with 100 µL of cold fixative solution (50% methanol/acetone), after 1h at room temperature the fixation solution was remove, the cells were washed with 200 µl PBS and plates were air dried. Out the BSL3 facility, an ELISA was performed for visualization of cell infection by stained the cells with a polyclonal rabbit anti-SARS-CoV antibody (provided by Dr. M. Dominguez, CNM-ISCIII). An optimal concentration of a secondary peroxidase-labeled goat anti-rabbit IgG (Dako, <https://www.agilent.com>) was included. Signal developed was obtained by using a prepared substrate (10 mg OPD in 20 mL citrate buffer and H₂O₂), stop solution was added and the absorbance was read at 490nm (OD₄₉₀).

Results were measured as titers of neutralizing antibodies and were calculated as the highest dilution resulting in an infection reduction of >50% (VMNT-ID₅₀). In every plate, controls were included to verified the whole assay. Six-well virus control should have an OD₄₉₀>0.8 and 6-well cell control should have an OD₄₉₀<0.2

1. Okba N, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe Acute Respiratory Syndrome Coronavirus 2–Specific Antibody Responses in Coronavirus Disease Patients. *Emerg Infect Dis.* 2020;26(7):1478-1488. <https://dx.doi.org/10.3201/eid2607.200841>
2. Amanat, F., Stadlbauer, D., Strohmeier, S. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med* 26, 1033–1036 (2020). <https://doi.org/10.1038/s41591-020-0913-5>

Additional details on protocol changes

The final protocol is included in the supplementary material to this publication. Changes made to the protocol are summarised below:

<u>Protocol versions</u>	<u>Amendment description</u>
v.1 22/03/2020	Version first approved by Research Ethics Committee. No approval by the Medicines Competent Authority was deemed necessary (blood product)

v.1.1 31/03/2020	Version approved with an updated enclosed list of participating centers and transfusion centers as well as local investigators. Updated Patient and Donor Informed Consent V1 26/03/2020. No methodological amendments.
v.2 06/04/2020	<p>Amendment to change inclusion criteria:</p> <ul style="list-style-type: none"> -The limit of maximum of three days from admission to randomization was withdrawn. It was considered the relevant limits were those based on the days elapsed since the beginning of the symptoms until randomization. -The 72-hour window for the SARS-CoV-2 positive RT-PCR was withdrawn and changed for a valid positive RT-PCR obtained in the current course of the disease. This was prompted by the fact that some patients experienced worsening and admission a few days after their diagnosis together with the huge overload of local laboratories. A new basal RT-PCR was to be collected and sent to the central laboratory of the trial, but there were no need to repeat the local RT-PCR for inclusion. -The limit of 10 days of symptoms was extended to 12 days of symptoms. This was due to the evidence of a number of candidate patients being admitted around 10 days of symptoms together with data published of series of cases informing of no risk in patients with longer disease evolution. <p>The possibility to include patients with longer duration of symptoms if negative for SARS-CoV-2 antibodies was removed by logistical reasons. The need to confirm negative for SARS-CoV-2 antibodies for patients with more than 10 days of symptoms was removed based on the absence of safety concerns in the series of patients treated with CP (with much longer disease evolution).</p> <ul style="list-style-type: none"> -Explicit mention to the need to include ABO group determination at baseline was added.
v.2.1 14/04/2020	<ul style="list-style-type: none"> -Description of categories 4 and 5 of the ordinal scale was reworded to state that patients with oxygen mask with reservoir bag were considered category 4. -Determination of IL-6 was added to the laboratory parameters
v.2.2 22/04/2020	<ul style="list-style-type: none"> -The requirement that plasma donors must submit a negative PCR for SARS-CoV2 in nasopharyngeal or oropharyngeal smears was removed. The change followed the publication of the revised EU Guidance on collection, testing, processing, storage, distribution and monitored use of COVID-19 convalescent plasma, which does not include this requirement from its Version 1.0 April 4 2020. <p>As it was not required anymore, it is a bothersome test for the donor and the plasma inactivation gives further reassurance about viral elimination, the test was removed from the protocol.</p> <ul style="list-style-type: none"> -The description of Adverse Events of Special Interest (TRALI, ADE and TACO) was included in the protocol
<u>Amendment on date 26/05/2020.</u> <u>No change in protocol version</u>	The amendment aims to allow an extended follow up of patients by adding a substudy on COVID-19 recrudescences. The objective of this substudy is to describe the frequency and the clinical, analytical, radiological and microbiological characteristics of recrudescences in patients with Covid-19. The amendment includes a new version of the Informed Consent with the mention to the substudy and a brief protocol for the RECOVID substudy. The original protocol was not amended.

Additional details on statistical analysis

DSMB assessments and Steering Committee decisions.

An assessment, restricted to safety objectives, was performed by the DSMB after first 20 patients and a recommendation to follow with the study was issued.

On 10 June, the DSMB performed the first planned safety and futility analysis (at 20% recruitment). The analysis was based on data cut-off of 3 June with 77 recruited patients. The recommendation of the DSMB was to follow without changes. However, on 10 July, the Steering Committee decided to stop recruitment due to the drastic fall in recruitment related to pandemic control in Spain (only 6 new patients in 5 weeks) that anticipates several months before reaching second interim analysis, at the time sound suggestions to refine the trial design were present. The proposed revision of the design aim to select patients without antibodies against SARS-CoV-2 and to extend patients follow-up to capture potential effect on late and serious COVID-19 complications.

3. Supplementary Tables

Table S1. Demographic and Clinical Characteristics of the Patients at Baseline (Intention-to-Treat population *)

Characteristic	Plasma + SOC (N=38)	SOC (N=43)	All (N=81)
Age, mean±SD — yr	61.3 ±16.3	60.3 ±15.0	60.8 ±15.5
Age, median (IQR) — yr	60.5 (46.0-74.0)	58.0 (51.0-73.0)	59.0 (49.0- 74.0)
Male sex — no. (%)	20 (52.6)	24 (55.8)	44 (54.3)
Median time (IQR) from symptom onset to hospitalization — days	5.5 (4.0-7.0)	5.0 (2.0-7.0)	5.0 (3.0-7.0)
Median time (IQR) from symptom onset to randomization — days	8.0 (7.0-9.0)	8.0 (6.0-9.0)	8.0 (6.0-9.0)
Body temperature— °C	36.7±0.9	36.5±0.9	36.6±0.9
Oxygen saturation— %	95.3±2.5	94.9±2.2	95.1±2.3
Oxygen Liters per minute —	4.9±5.8	4.8±6.1	4.8±5.9
Coexisting conditions— no. (%)			
Diabetes mellitus	12 (31.6)	5 (11.6)	
Hypertension	20 (52.6)	12 (27.9)	
Cardiovascular disorder	6 (15.8)	9 (20.9)	
Chronic lung disease	2 (5.3)	8 (18.6)	
Chronic Kidney disease	2 (5.3)	2 (4.7)	
Immunodeficiency	2 (5.3)	5 (11.6)	
Bilateral Pneumonia at Rx— no. (%)	35 (92.1)	37 (86.1)	72 (88.9)
Standard of care treatments— no. (%)			
Hydroxychloroquine	34 (89.47)	36 (83.72)	70 (86.42)
Lopinavir-ritonavir	15 (39.47)	19 (44.19)	34 (41.98)
Azithromycin	24 (63.16)	26 (60.47)	50 (61.73)
Remdesivir	1 (2.63)	3 (6.98)	4 (4.94)
Glucocorticoid therapy	21 (55.26)	25 (58.14)	46 (56.79)
Tocilizumab	10 (26.32)	13 (30.23)	23 (28.40)
Low Molecular Weight Heparin	27 (71.05)	33 (76.74)	60 (74.07)
Score on ordinal scale— no. (%)			
3. Hospitalized, not requiring supplemental oxygen	10 (26.32)	13 (30.23)	23 (28.40)
4. Hospitalized, requiring supplemental oxygen by mask or nasal prongs	28 (73.68)	30 (69.77)	58 (71.60)
IgG positive for anti SARS-Cov-2 antibodies (ELISA) — no. (%)	21 (55.26)	19 (44.19)	40 (49.38)

*Plus-minus values are mean ±SD. The intention to treat population includes all randomized patients.

Table S2. Demographic and Clinical Characteristics of Donors

Characteristic	Donors of plasma used (N=26)
Age, mean \pm SD — yr	37.85 (11.60)
Male sex — no. (%)	23 (88.46)
Median time (IQR) of symptom duration — days	13.00 (8.00-16.00)
IgG positive for anti SARS-Cov-2 antibodies (ELISA) — no. (%)	24 (92.31) *
Semiquantitative results for anti SARS-Cov-2 antibodies (ELISA), median (IQR)	4.00 (2.09, 5.70)
ID50 for D614 pseudovirus neutralizing assay, median (IQR),range	310 (168-882) Range 40-3319
PRNT50 neutralizing AB titer, median (IQR), range	291 (238-451) Range 109-1019

*At the very beginning of the trial, several ELISA tests were tested and validated with the initial donors. Two donors were considered positive based on initial local laboratory results but were later on classified as indeterminate according to the central laboratory trial result (Euroimmun, ELISA). Both plasmas had titers of neutralizing antibodies above 1:80 and were used in trial patients.

Table S3. Characteristics of Plasma received by the patients. Data differ from characteristics in table s2 because some donors provide plasma for two patients.

Characteristic	Patients N=37
Semiquantitative results for anti SARS-Cov-2 antibodies (ELISA), median (IQR)	3.65 (IQR 2.0-5.3) Range (0.4-6.8)
ID50 for D614 pseudovirus neutralizing assay, median (IQR), range *	327.3 (IQR 168.1-882.1), Range 40.2*-3319.0
PRNT50 neutralizing AB titer, median (IQR)	292.2 (IQR 237.7- 450.7) Range 109.4-1018.7

*One plasma (received by two patients) showed a neutralizing titer below 1/80 with the pseudovirus assay. This plasma had positive IgG values with Euroimmun test and neutralization titer of 1: 238 with the PRNT test.

Table S4. Distribution of ordinal scale status over time and per treatment groups.

Group PLASMA N=38																		
	Day1 (Bas)	Day2	Day3	Day4	Day5	Day6	Day7	Day8	Day9	Day10	Day11	Day12	Day13	Day14	Day15	Day 15 CUM	Day29	Day 29 CUM
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Not evaluated	0 (0)	0 (0)	0 (0)	3 (7.9)	0 (0)	9 (23.7)	12 (31.6)	3 (7.9)	16 (42.1)	19 (50)	5 (13.2)	23 (60.5)	24 (63.2)	25 (65.8)	0 (0)	0 (0)	0 (0)	0 (0)
1. Not hospitalized, no limitations on activities	0 (0)	0 (0)	2 (5.3)	0 (0)	5 (13.2)	1 (2.6)	0 (0)	8 (21.1)	1 (2.6)	2 (5.3)	14 (36.8)	2 (5.3)	2 (5.3)	2 (5.3)	23 (60.5)	23 (60.5)	27 (71.1)	27 (71.1)
2. Not hospitalized, limitation on activities	0 (0)	1 (2.6)	1 (2.6)	0 (0)	4 (10.5)	3 (7.9)	4 (10.5)	5 (13.2)	5 (13.2)	2 (5.3)	5 (13.2)	1 (2.6)	1 (2.6)	2 (5.3)	7 (18.4)	7 (18.4)	7 (18.4)	7 (18.4)
3. Hospitalized, not requiring supplemental oxygen	10 (26.3)	10 (26.3)	11 (28.9)	12 (31.6)	11 (28.9)	7 (18.4)	6 (15.8)	7 (18.4)	5 (13.2)	6 (15.8)	6 (15.8)	3 (7.9)	4 (10.5)	2 (5.3)	4 (10.5)	4 (10.5)	0 (0)	0 (0)
4. Hospitalized, requiring supplemental oxygen	28 (73.7)	27 (71.1)	24 (63.2)	22 (57.9)	17 (44.7)	17 (44.7)	15 (39.5)	13 (34.2)	10 (26.3)	8 (21.1)	7 (18.4)	9 (23.7)	7 (18.4)	7 (18.4)	4 (10.5)	4 (10.5)	4 (10.5)	4 (10.5)
5. Hospitalized, on non-invasive ventilation or high flow oxygen devices	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (5.3)	1 (2.6)	1 (2.6)	1 (2.6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
6. Hospitalized, on invasive mechanical ventilation or ECMO	0 (0)	0 (0)	0 (0)	1 (2.6)	1 (2.6)	1 (2.6)	1 (2.6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
7. Death	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Assessments were performed daily until discharge and at day 15 and 29.

Group Standard of Care N=43																		
	Day1 (Bas)	Day2	Day3	Day4	Day5	Day6	Day7	Day8	Day9	Day10	Day11	Day12	Day13	Day14	Day15	Day 15 CUM	Day29	Day 29 CUM*
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Not evaluated	0 (0)	0 (0)	2 (4.7)	5 (11.6)	2 (4.7)	8 (18.6)	14 (32.6)	10 (23.3)	20 (46.5)	22 (51.2)	19 (44.2)	29 (67.4)	34 (79.1)	34 (79.1)	4 (9.3)	0 (0)	5 (11.6)	0 (0)
1. Not hospitalized, no limitations on activities	0 (0)	0 (0)	3 (7)	0 (0)	5 (11.6)	2 (4.7)	1 (2.3)	7 (16.3)	1 (2.3)	4 (9.3)	8 (18.6)	1 (2.3)	1 (2.3)	1 (2.3)	24 (55.8)	24 (55.8)	29 (67.4)	29 (67.4)
2. Not hospitalized, limitation on activities	0 (0)	1 (2.3)	0 (0)	0 (0)	2 (4.7)	6 (14)	2 (4.7)	4 (9.3)	2 (4.7)	3 (7)	4 (9.3)	2 (4.7)	0 (0)	2 (4.7)	9 (20.9)	9 (20.9)	5 (11.6)	6 (14)
3. Hospitalized, not requiring supplemental oxygen	13 (30.2)	11 (25.6)	12 (27.9)	13 (30.2)	9 (20.9)	9 (20.9)	9 (20.9)	7 (16.3)	9 (20.9)	5 (11.6)	3 (7)	3 (7)	2 (4.7)	2 (4.7)	2 (4.7)	2 (4.7)	0 (0)	0 (0)
4. Hospitalized, requiring supplemental oxygen	30 (69.8)	28 (65.1)	25 (58.1)	24 (55.8)	23 (53.5)	16 (37.2)	15 (34.9)	14 (32.6)	10 (23.3)	8 (18.6)	8 (18.6)	6 (14)	5 (11.6)	3 (7)	2 (4.7)	2 (4.7)	1 (2.3)	1 (2.3)
5. Hospitalized, on non-invasive ventilation or high flow oxygen devices	0 (0)	1 (2.3)	1 (2.3)	1 (2.3)	1 (2.3)	1 (2.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2.3)	1 (2.3)	2 (4.7)	2 (4.7)
6. Hospitalized, on invasive mechanical ventilation or ECMO	0 (0)	0 (0)	0 (0)	0 (0)	1 (2.3)	1 (2.3)	1 (2.3)	1 (2.3)	1 (2.3)	1 (2.3)	1 (2.3)	1 (2.3)	1 (2.3)	1 (2.3)	1 (2.3)	1 (2.3)	1 (2.3)	1 (2.3)
7. Death	0 (0)	2 (4.7)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2.3)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2.3)	0 (0)	0 (0)	0 (0)	4 (9.3)	0 (0)	4 (9.3)

Assessments were performed daily until discharge and at day 15 and 29.

* One patient lost for follow-up after discharge. LOCF is performed

Overall follow-up assessment for change against baseline in the 7-points ordinal scale: Proportional odds model adjusting by stratification variables, OR (95%CI): 0.4079 (0.1063 to 1.5653)

Label	Estimate	Estimates			Pr > t	Exponentiated Estimate
		Standard Error	DF	t Value		
CP Vs SOC	-0.8967	0.6861	872	-1.31	0.1916	0.4079

Van Elteren test : Not assessable due to small numbers and the heterogeneity in the treatment by site distribution

Statistic	Alternative Hypothesis	Cochran-Mantel-Haenszel Statistics (Modified Ridit Scores)		Value	Prob
		DF			
1	Nonzero Correlation	1		11.9241	0.0006
2	Row Mean Scores Differ	2		.	.

Table S5. Mean change in the ordinal scale at scheduled assessments

		Group 1 (N=38)	Group 2 (N=43)	P Value Test
Day 03	n	38	41	Wilcoxon: 0.3471
	Missing	0	2	
	Mean (SD)	0.24 (0.59)	0.17 (0.67)	
	Median [Q1,Q3]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	
	Min, Max	0.00, 2.00	-1.00, 3.00	
Day 05	n	38	41	Wilcoxon: 0.1667
	Missing	0	2	
	Mean (SD)	0.58 (1.06)	0.29 (0.93)	
	Median [Q1,Q3]	0.00 [0.00, 1.00]	0.00 [0.00, 0.00]	
	Min, Max	-2.00, 3.00	-2.00, 3.00	
Day 08	n	35	33	Wilcoxon: 0.7808
	Missing	3	10	
	Mean (SD)	0.91 (1.27)	0.79 (1.24)	
	Median [Q1,Q3]	0.00 [0.00, 2.00]	0.00 [0.00, 2.00]	
	Min, Max	-1.00, 3.00	-2.00, 3.00	
Day 11	n	33	24	Wilcoxon: 0.2413
	Missing	5	19	
	Mean (SD)	1.55 (1.33)	1.08 (1.44)	
	Median [Q1,Q3]	2.00 [0.00, 3.00]	1.00 [0.00, 2.00]	
	Min, Max	-1.00, 3.00	-2.00, 3.00	
Day 15	n	38	39	Wilcoxon: 0.9398
	Missing	0	4	
	Mean (SD)	2.03 (1.05)	1.95 (1.26)	
	Median [Q1,Q3]	2.00 [1.00, 3.00]	2.00 [2.00, 3.00]	
	Min, Max	0.00, 3.00	-2.00, 3.00	
Day 29	n	38	38	Wilcoxon: 0.8551
	Missing	0	5	
	Mean (SD)	2.24 (0.94)	2.13 (1.38)	
	Median [Q1,Q3]	2.00 [2.00, 3.00]	2.50 [2.00, 3.00]	
	Min, Max	0.00, 3.00	-3.00, 3.00	

*Wilcoxon test: Wilcoxon rank-sum test (Mann-Whitney test)

Table S6. Days free from oxygen support and ventilation per groups.

		Group 1 (N=38)	Group 2 (N=43)	P Value Test
Days of oxygen use	n	38	41	Wilcoxon: 0.8434
	Missing	0	2	
	Mean (SD)	6.24 (7.71)	5.51 (5.55)	
	Median [Q1,Q3]	4.00 [0.00, 8.00]	4.00 [1.00, 8.00]	
	Min, Max	0.00, 28.00	0.00, 28.00	
Oxygen free days	n	38	41	Wilcoxon: 0.3741
	Missing	0	2	
	Mean (SD)	6.37 (3.40)	5.95 (3.74)	
	Median [Q1,Q3]	6.00 [5.00, 8.00]	6.00 [4.00, 7.00]	
	Min, Max	0.00, 14.00	0.00, 15.00	
Day of mechanical ventilation use	n	38	41	Wilcoxon: 0.5953
	Missing	0	2	
	Mean (SD)	0.11 (0.65)	0.68 (3.25)	
	Median [Q1,Q3]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	
	Min, Max	0.00, 4.00	0.00, 19.00	
Ventilator free days	n	38	41	Wilcoxon: 0.3064
	Missing	0	2	
	Mean (SD)	12.61 (5.68)	11.46 (5.14)	
	Median [Q1,Q3]	11.00 [8.00, 15.00]	10.00 [9.00, 13.00]	
	Min, Max	6.00, 28.00	5.00, 28.00	

*Wilcoxon test: Wilcoxon rank-sum test (Mann-Whitney test)

Table S7. Serious or Grade 3-4 adverse events by treatment group

MedDRA System Organ Class	Preferred Term	Convalescent Plasma (n=38) n (%)	Standard of Care (n=43) n (%)
Patients with at least one serious or grade 3-4 adverse event*		6 (15.78)	7 (16.27)
Cardiac disorders	Syncope	1 (2.63)	0 (0.0)
Gastrointestinal disorders	Gastrointestinal hemorrhage	0 (0.0)	1 (2.32)
General disorders and administration site conditions	Pyrexia	1 (2.63)	0 (0.0)
Injury, poisoning and procedural complications	Transfusion reaction	2 (5.26)	0 (0.0)
Nervous system disorders	Cerebral infarction	0 (0.0)	1 (2.32)
	Hypoxic-ischemic encephalopathy	1 (2.63)	0 (0.0)
Respiratory, thoracic and mediastinal disorders	Acute respiratory distress syndrome	1 (2.63)	1 (2.32)
	Respiratory failure	0 (0.0)	2 (4.65)
	Pulmonary embolism	1 (2.63)	2 (4.65)
	Dyspnea	0 (0.0)	1 (2.32)
Skin and subcutaneous tissue disorders	Skin rash	1 (2.63)	0 (0.0)

*Three patients (2 in CP, 1 in SOC) experienced two events each. MedDRA version 21 was used

Table S8. Negativization over time of RT-PCR on serial oro/naso pharyngeal swabs (all patients). Not all patients had their samples collected at all scheduled timepoints. 79.7% of serial scheduled samples in the plasma group and 66.54% in the control group were obtained.


		Group 1 (N=38)	Group 2 (N=43)	P Value Test
Baseline				
NEGATIVE	n (%)	8 (21.05)	5 (11.63)	Fisher: 0.3583
POSITIVE	n (%)	26 (68.42)	34 (79.07)	
	n (%)	4 (10.53)	4 (9.30)	
Day3				
INDETERMINATE	n (%)	0 (0.00)	1 (2.33)	Fisher: 0.1246
NEGATIVE	n (%)	9 (23.68)	4 (9.30)	
POSITIVE	n (%)	24 (63.16)	31 (72.09)	
	n (%)	5 (13.16)	7 (16.28)	
Day5				
NEGATIVE	n (%)	14 (36.84)	7 (16.28)	Fisher: 0.0664
POSITIVE	n (%)	18 (47.37)	26 (60.47)	
	n (%)	6 (15.79)	10 (23.26)	
Day8				
NEGATIVE	n (%)	13 (34.21)	9 (20.93)	Fisher: 0.4226
POSITIVE	n (%)	16 (42.11)	18 (41.86)	
	n (%)	9 (23.68)	16 (37.21)	
Day11				
NEGATIVE	n (%)	9 (23.68)	11 (25.58)	Fisher: 0.2395
POSITIVE	n (%)	16 (42.11)	9 (20.93)	
	n (%)	13 (34.21)	23 (53.49)	
Day15				
NEGATIVE	n (%)	17 (44.74)	15 (34.88)	Fisher: 1.0000
POSITIVE	n (%)	15 (39.47)	15 (34.88)	
	n (%)	6 (15.79)	13 (30.23)	
Day29				
NEGATIVE	n (%)	22 (57.89)	15 (34.88)	Fisher: 0.1588
POSITIVE	n (%)	7 (18.42)	12 (27.91)	
	n (%)	9 (23.68)	16 (37.21)	

Table S9. RT-PCR evolution in blood samples.

		Group 1 (N=38)	Group 2 (N=43)	P Value Test
Baseline				
NEGATIVE	n (%)	31 (81.58)	35 (81.40)	Fisher: 1.0000
POSITIVE	n (%)	6 (15.79)	6 (13.95)	
	n (%)	1 (2.63)	2 (4.65)	
Day3				
NEGATIVE	n (%)	28 (73.68)	30 (69.77)	Fisher: 0.7831
POSITIVE	n (%)	7 (18.42)	10 (23.26)	
	n (%)	3 (7.89)	3 (6.98)	
Day5				
NEGATIVE	n (%)	32 (84.21)	34 (79.07)	Fisher: 0.4378
POSITIVE	n (%)	2 (5.26)	5 (11.63)	
	n (%)	4 (10.53)	4 (9.30)	
Day8				
NEGATIVE	n (%)	30 (78.95)	26 (60.47)	Fisher: 0.4180
POSITIVE	n (%)	2 (5.26)	4 (9.30)	
	n (%)	6 (15.79)	13 (30.23)	
Day11				
NEGATIVE	n (%)	25 (65.79)	17 (39.53)	Fisher: 0.3029
POSITIVE	n (%)	1 (2.63)	3 (6.98)	
	n (%)	12 (31.58)	23 (53.49)	
Day15				
NEGATIVE	n (%)	34 (89.47)	29 (67.44)	Fisher: 0.1084
POSITIVE	n (%)	0 (0.00)	3 (6.98)	
	n (%)	4 (10.53)	11 (25.58)	
Day29				
NEGATIVE	n (%)	34 (89.47)	25 (58.14)	Fisher: 0.3148
POSITIVE	n (%)	1 (2.63)	3 (6.98)	
	n (%)	3 (7.89)	15 (34.88)	

4. Supplementary Figures

Figure S1. Hyperimmune Convalescent Plasma (CP) donors, apheresis and CP units.



*Due to adverse events or technical failure.

Figure S2. D614 Pseudovirus Assay. Titers of neutralizing antibodies.




Figure S3. Neutralization antibodies titers in donors. D164 Pseudovirus assay

Neutralization of SARS-CoV-2 pseudovirus

